NH Hospital's innovative approach to mental health is based on the patient's biochemical makeup and gene-environment interfaces. Photo courtesy of NH Hospital

There's no one-size-fits-all solution to medical care. NH Hospital is bringing innovative technologies and functional medicine to patients in the Houston area. Using patients' biochemical makeup, the medical provider has created a unique service for Houstonians seeking a multi-pronged approach to behavioral health and substance use disorders.

The past year has been an incubator for mental health issues. Pandemic isolation, social distancing, financial instability, racial reckonings, and a massive death toll have posed an enormous threat to the mental wellbeing of people around the world. Experts predict a long-term spike in post-traumatic stress disorder (PTSD) cases as society grapples with the tragedies of the last year, but the toll is already here.

A recent Centers for Disease Control and Prevention (CDC) study found that the percentage of adults with recent symptoms of anxiety or depression increased from 36.4 to 41.5 percent between Aug. 19, 2020, and Feb. 1, 2021.

As the world waits for a moment to exhale after a catastrophic year, NH Hospital keeps busy serving patients struggling with both behavioral health and addiction during the pandemic. Outside of depression and anxiety, the facility also treats bipolar disorder, PTSD, codependency, and postpartum depression by using a multidisciplinary approach.

NH Hospital integrates traditional medicine with functional medicine with a mission of treating the root cause of an issue and not just the symptoms. From providing an on-site chef and nutritionist to stimulating patients with calming acoustic therapy, the facility blends unique treatment modalities that address the whole body rather than an isolated issue.

"With functional medicine, we find other avenues and ways to allow [patients] to heal and to change their behavior," explains Debbie Cormier, CEO of NH Hospital.

Using genetic markers as a roadmap to health

You can build the closet of Carrie Bradshaw's dreams online, buy bespoke cologne based on your body chemistry, monogram jewelry and clothing, and even get a Renaissance-style portrait of your family pet. Tailor-made options are ubiquitous; why not customize medical care?

"For years, the traditional way, we just gave people the same amount of meds, the same diets, the same everything," and wondered why some patients responded better or quicker than others, explains Cormier. For the unlucky patients who didn't get stellar results, she says doctors may have thought "they just have to deal with it" and wait. "We don't feel that you should have to just deal with it," she continues.

When treating a patient, NH Hospital doctors consider the genetic makeup of each patient to create a custom care plan. With tests as simple as a swab of the cheek, the facility can gather biochemical markers that can share valuable medical information like risk factors for diseases.

Cormier believes NH Hospital's ability to look at a patient's genetic background and "treat you as an individual," is a key factor that sets the facility apart. The hospital also focuses on understanding how your genes interact with your environment.

Think of gene-environment interactions as nature vs. nurture, an ideology that research suggests plays significant roles in the outset of mental illness. Genetic and environmental factors interact to influence phenotype, the observable characteristics you exhibit when your genotype and environment interact.

When these factors are off-balance, it can result in undesirable results. A 2001 study of Finnish twins studied the socio-geographic impact on adolescent alcohol use in urban and rural environments. While the frequency of alcohol use was the same in both settings, the factors that led adolescents to drink were entirely different. Genetic factors played a larger role in urban areas, whereas the shared environment had a greater influence in rural settings.

By applying various modalities based on genetic information, doctors aren't going in blind and "know you from the inside out," says Cormier.

When a patient comes in struggling with something as grappling as depression or anxiety, conditions they've seen an uptick in since the beginning of the pandemic, doctors will run a genetic test as well as traditional lab work. Cormier says some potential treatment paths may include photosynthesis therapy, hydration therapy and nutrition.

Dietetics meets tech

NH Hospital helps patients get micronutrient infusions, but its nutrition program provides an integrated approach to fueling the body with the help of a staff chef.

"We only have so much energy every day, and we choose how we use the energy but by getting your diet right, it starts to heal you in all kinds of ways," says Cormier.

While the physical repercussions of a poor diet like diabetes and heart disease are widely known, you may be surprised to hear that nutrition can affect mood disorders and harm brain cells. According to Harvard Health Publishing, refined sugars can lead to brain impairment, depression and oxidative stress — the free radicals produced when the body uses oxygen, which can damage cells. By focusing on a patient's nutrition, "the person has a better chance to heal, not only from the issue that is brought to us but to overall feel good," she says.

Counseling, cryotherapy, transcranial magnetic stimulation and cocoon therapy therapies are just some of the other methods NH Hospital doctors use to treat their patients.

Cormier recalls the recovery of a patient who was experiencing depression and using a wheelchair due to pain in her knees. She gradually gained the ability to walk without pain again after a months-long treatment plan of cryotherapy and micronutrient infusions.

"She said that we really changed her life because we gave her back her life. Now she's walking a mile a day around her block and she's able to do daily moving. She said she hadn't done that in years," says Cormier.

A mission to heal

Outside of neuropsychology, NH Hospital offers medical detox with monitoring from trained professionals and therapy plans for patients coming off of alcohol, methamphetamine, heroin, opioids like fentanyl and other prescription drugs.

Since the U.S. The Department of Health and Human Services declared the opioid epidemic as a public health emergency in 2017, nearly 841,000 people have died of an opioid overdose. Like anxiety and depression, addiction is also on the rise during the pandemic. A CDC survey found that 13 percent of respondents began using drugs during the pandemic or increased their use of illicit substances.

NH Hospital doctors provide micronutrients among other aides to help "build [patients] up] before taking them off the drugs, says Cormier. "We're just trying to make sure the patient feels safe and that if we're doing all these things, we continue to move them in a positive direction instead of just letting them sweat it out," she says.

"Our leadership here is committed to doing what it takes to help people whether they have behavioral, medical, or whatever [condition] brings them through our doors so that we make them have a better life," says Cormier.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Eli Lilly breaks ground on $6.5B pharmaceutical factory in Houston

lilly lands

Leading pharmaceutical company Eli Lilly broke ground today, Sept. 21, on its $6.5 billion manufacturing site at Houston's Generation Park.

The 236-acre, state-of-the art factory is expected to come online in 2030 and will manufacture Foundayo, the company's first synthetic oral GLP-1 medication, as well as other advanced therapeutics.

"We are thrilled to break ground on our latest ‘medicines made in America’ site in the great state of Texas," David Ricks, Lilly chair and CEO, said in a prepared statement. "This $6.5 billion investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly’s latest products from Texas to people here at home and around the world.”

Houston was up against more than 300 locations in the U.S. for the factory, as part of Lilly’s $50 billion investment in domestic medicine production that has launched 10 manufacturing sites since 2020. Lilly first announced Houston had been selected for the site last September.

Photo via gov.texas.gov

As Abbott mentioned, the site is expected to create hundreds of jobs, and will hire engineers, scientists, operations personnel and lab technicians once up and running. It will create 4,000 construction jobs while being built.

In an effort to support workforce development, Lilly also announced a $12.5 million commitment to Houston's San Jacinto College in addition to a $2.5 million charitable donation to the San Jacinto College Foundation. The funding will go toward hands-on training, equipment and facilities to support future technicians, operators, maintenance professionals, and other manufacturing talent, according to Lilly. The charitable donation will fund scholarships for students.

"This relationship will build a strong, sustainable talent pipeline for Lilly while creating meaningful, high-demand career opportunities across our region,” Brenda Hellyer, chancellor of San Jacinto College, said in the release.

"When you invest in a place like Houston, you invest in its people first," Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, added. "This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We're hiring across the greater Houston area to help residents build careers close to home."

Rendering courtesy Eli Lilly

Lilly previously said it chose Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, because of factors such as financial incentives, access to utilities and transportation and the region’s business-friendly environment. Generation Park is home to campuses for San Jacinto College and Lone Star College.

Since Lilly first announced plans for the site, another fellow pharma giant has made plans to move into Generation Park. Bristol Myers Squibb Co. announced last month that it would build a $2.3 billion factory in the district. The site is expected to manufacture small molecule, biologic and antibody-drug conjugates and will also come online around 2030. Read more here.

UH Health names leader of new digital health institute

new exec

Recently launched UH Health has named the first-ever executive director of its new Institute for Digital Healthcare Transformation at the University of Houston.

Beto López has been tapped to lead the new initiative that aims to help develop and commercialize health care technologies centered around university research.

Launched in August, the Institute for Digital Healthcare Transformation leans on experts from UH’s engineering, medicine, business, law and other departments and will connect with industry partners. It will initially focus on mobile health applications, sensors, wearables and artificial intelligence, according to UH.

“Most digital health initiatives and commercialization efforts start with the technology and hope adoption follows. But the translation gap isn't a science problem — it’s a scaffolding problem between researchers, the community and the market,” López said in a news release. “I've spent the past 10 years building that scaffolding in places that weren’t wired for it, and I'm looking forward to building it here at UH to help ensure new health care technologies reach the people and communities that can benefit from them most.”

López previously spent 10 years at San Francisco-based innovation consultancy company IDEO, where he led over 100 projects for Fortune 500 companies and public agencies. He co-founded and served as managing director of the Design Institute for Health at UT Austin’s Dell Medical School; and also co-founded a social venture studio/venture capital fund focused on health care innovation. He worked alongside Houston’s Legacy Community Health during the COVID-19 pandemic.

“Beto understands that breakthrough technology alone doesn't transform health care — it has to be designed around the needs of patients, providers and communities and have a clear path into practice,” Jonathan McCullers, vice president for health affairs at UH, added in the news release. “His experience spanning academic health care and venture capital equips him to bring together researchers, health care organizations, entrepreneurs and investors. This makes him uniquely suited to lead this institute and help turn the university's innovation into solutions that improve people's lives.”

The University of Houston launched UH Health, its new cross-disciplinary academic venture, in July. It aims to bring together the university's health-related education, research and community impact under one umbrella.

ExxonMobil gets approval for $5B Texas Gulf Coast carbon capture project

CCS Expansion

Spring-based ExxonMobil has won approval from the Texas Railroad Commission for a $5 billion carbon capture and storage project in East Texas.

Dominic Genetti, senior vice president of CCS at ExxonMobil, told The Financial Times, which broke the news, that the Railroad Commission’s action is a “major milestone” that lets the company keep expanding along the Gulf Coast. In a 2-1 vote, commissioners authorized a carbon sequestration permit for the project.

“The Railroad Commission clearly recognizes the important role carbon capture and storage can play in meeting growing global demand for lower-carbon products while supporting new jobs and economic growth,” Genetti said.

The U.S. Environmental Protection Agency (EPA) approved ExxonMobil’s Rose CCS project last year.

The project will enable the company to inject about 53 metric tons of industrial customers’ carbon emissions into three underground wells it drilled in the Beaumont-Port Arthur area. Over a 13-year period, ExxonMobil plans to inject about 4 million metric tons per year into the Fleming and Upper Frio rock formations, according to Carbon Herald.

ExxonMobil says it owns the world’s first and largest CCS system, comprising 1,300 miles of CO2 pipeline and secure storage sites. Seventy percent of the pipelines are along the Gulf Coast.

The company ramped up its CCS business in 2023 with the $4.9 billion purchase of Denbury, which owned about 1,000 miles of CO2 pipelines.

“Our expertise, combined with Denbury’s talent and CO2 pipeline network, expands our low-carbon leadership and best positions us to meet the decarbonization needs of industrial customers while also reducing emissions in our own operations,” ExxonMobil Chairman and CEO Darren Woods said when the deal closed.

In January, Genetti wrote in a post on ExxonMobil’s website that the company is committed to CCS “for the long haul.”

“CCS is not new technology, but it’s flown relatively under the radar compared with the attention that production of hydrocarbons commands,” he wrote. “Now, as the world becomes more aware of the need to reduce emissions, CCS finally has a brighter spotlight and a broader runway to scale up.”

The company also announced this week that it has begun CCS operations at a direct reduced iron facility in Convent, Louisiana. The project will capture, transport and store up to 800,000 metric tons of CO2 per year, according to the company.

---

This article first appeared on EnergyCapitalHTX.com.